Novo Nordisk A/S with ticker code (NVO) have now 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 148.84 and 121.5 and has a mean target at 135.29. With the stocks previous close at 132.58 this is indicating there is a potential upside of 2.0%. The 50 day moving average now sits at 125.11 while the 200 day moving average is 112.72. The company has a market capitalisation of $300,677m. You can visit the company’s website by visiting: https://www.novonordisk.com
The potential market cap would be $306,823m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
